Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.
about
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).Optimizing antimicrobial therapy in critically ill patientsDetermination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging.Antimicrobial-induced DNA damage and genomic instability in microbial pathogensIn-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleriPharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosisNoninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected miceMicrodialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution.Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients.Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboonsNuclear imaging: a powerful novel approach for tuberculosis.Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug.Human tissue distribution of voriconazole.Pharmacokinetic study on pradofloxacin in the dog - comparison of serum analysis, ultrafiltration and tissue sampling after oral administrationRadiosynthesis and biological evaluation of a novel enoyl-ACP reductase inhibitor for Staphylococcus aureusPopulation Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI).Interspecies pharmacokinetics and in vitro metabolism of SQ109.Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance.Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model.Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: in vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse modelComparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin.Radiolabelling and positron emission tomography of PT70, a time-dependent inhibitor of InhA, the Mycobacterium tuberculosis enoyl-ACP reductase.Liposomal doxorubicin extravasation controlled by phenotype-specific transport properties of tumor microenvironment and vascular barrier.Future in vitro and animal studies: development of pharmacokinetic and pharmacodynamic efficacy predictors for tissue-based antibiotics.Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia.In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis.Mechanism of action and initial evaluation of a membrane active all-D-enantiomer antimicrobial peptidomimeticPharmacodynamic variability beyond that explained by MICs.PET and SPECT radiotracers to assess function and expression of ABC transporters in vivoApproaches using molecular imaging technology -- use of PET in clinical microdose studies.Tissue accumulation of cephalothin in burns: a comparative study by microdialysis of subcutaneous interstitial fluid cephalothin concentrations in burn patients and healthy volunteers.Enantiomeric radiochemical synthesis of R and S (1-(6-amino-9H-purin-9-yl)-3-fluoropropan-2-yloxy)methylphosphonic acid (FPMPA)Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem celTissue penetration of antifungal agents.[18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans.Drug penetration and metabolism in 3D cell cultures treated in a 3D printed fluidic device: assessment of irinotecan via MALDI imaging mass spectrometry.Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.Understanding the pharmacokinetics of tulathromycin: a pulmonary perspective.Role of microdialysis in pharmacokinetics and pharmacodynamics: current status and future directions.A comprehensive review on the pharmacokinetics of antibiotics in interstitial fluid spaces in humans: implications on dosing and clinical pharmacokinetic monitoring.
P2860
Q26739860-BB3545EA-12C4-4484-968C-2DFD8B3642B6Q26999905-420CF31F-2560-487F-B3AF-D9AA86A9CE8BQ27324299-2D5FA9DE-1301-4805-A0FF-C15987B61154Q27693195-CF5DF0BC-2A3F-46DC-8527-1EC1C0568C1AQ28304841-D85153B9-A809-4152-BAD2-7BC2A9D3C4E7Q28542435-16C54DEB-C16E-469C-8646-C06C1ABB2D10Q30421576-0BE28FAF-6B34-4B6F-9B4A-E25FDF463C15Q31046210-0FC61ED5-C006-4942-A9FB-2A363E7356E5Q33802909-45617B41-1998-4780-8B83-4D202789B9C4Q33835981-6216C91A-738B-4A39-A760-DE0155E2418BQ34315731-D1AA0B7D-0461-45F1-A7E3-7828E45D9913Q34383718-63DB1E2A-F852-4CD0-B01E-FA4B0CF160B5Q34529318-F7AADC5B-5B2F-4A9A-BEB4-2C408D68A6C0Q34587450-B3DA9158-9D07-45A9-B1D5-0B7BC4E01749Q34622399-799BECAE-B5AC-4A4B-92D3-4C1708FE7BF9Q34726196-8B43C778-4ECC-444C-97E4-7FBCA8875C2EQ35100649-0F2FFB5C-4B26-472A-B8C5-839FDB3BC8BDQ35699612-71FF6E36-7166-4F6F-8FE5-AE156220B7A3Q35941253-346A501B-A682-46B5-8AF2-264A59698483Q35955162-0155A013-C70B-4635-AA7E-F3B8967AB3F2Q35959546-A73A7A41-80E0-4075-A451-4CD21B78397EQ36167169-DECD9C3C-EC39-498A-96B8-883B39BC5315Q36217918-E8C29B8F-E7B8-4B73-8FE5-0F865F27EA73Q36320608-ACD5A245-F948-4FB9-BA80-7B36920062D8Q36428418-2DE94DEA-7D77-4AA3-97C2-84281E43A2E5Q36571906-2A18BF24-E2AB-4F57-A30F-CFA5008CD7F7Q36653632-F1EBAEBF-A341-42E1-AEAA-3CDD6D18E9C4Q36757639-763E7C1E-17F9-4BA3-832B-00A63B40D9EEQ36953090-F5C82ABB-CFC9-49AE-A30C-A12B1A81BFDAQ36953094-D11E20DD-30F2-49CB-B28B-45E08DA4EE54Q37032883-D3F497EA-3B04-4A61-8757-2D83449EB60BQ37326178-2C930B36-D455-49B0-83A7-C3994B95A294Q37333175-8F0F75B7-733C-4BA9-B2C6-550A17C49B91Q37544911-8ED3A208-35AA-4359-9FD3-CC4A91BBB86AQ37568411-015D16E0-2F72-482A-964E-B2AAEE2D0FB3Q37643787-AAF218BA-9AD3-488D-9943-85FD13708925Q37927017-336EAE1E-284F-4008-9345-63DABDD27097Q38151858-F2707506-7AB2-4F5C-B2C7-C81F7FFCAA73Q38181011-ACDB51D0-B517-43CF-BDFE-0A73DC274258Q38223948-9FF2E7A3-FBD6-47D0-8D32-59E66F6A5DE0
P2860
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Issues in pharmacokinetics and ...... gents: distribution in tissue.
@ast
Issues in pharmacokinetics and ...... gents: distribution in tissue.
@en
type
label
Issues in pharmacokinetics and ...... gents: distribution in tissue.
@ast
Issues in pharmacokinetics and ...... gents: distribution in tissue.
@en
prefLabel
Issues in pharmacokinetics and ...... gents: distribution in tissue.
@ast
Issues in pharmacokinetics and ...... gents: distribution in tissue.
@en
P2093
P2860
P1476
Issues in pharmacokinetics and ...... gents: distribution in tissue.
@en
P2093
Amparo dela Peña
Hartmut Derendorf
Markus Müller
P2860
P304
P356
10.1128/AAC.48.5.1441-1453.2004
P407
P577
2004-05-01T00:00:00Z